Novartis just reported a solid Q2 with $14.4B in net sales, up 3% in dollar terms, fueled by explosive growth in newer drugs like Kisqali, Scemblix, Kesimpta, and Pluvicto — even as their once-dominant heart drug Entresto tanked 50% due to generics and upcoming patent expirations. Despite the mixed results, the company reaffirmed its 2026 outlook, eyeing low-single-digit sales growth and new acquisitions like Myricx Bio to bolster its pipeline, while also hitting key regulatory milestones in Europe, Japan, and the U.S.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
